Treatment regimens for rifampicin-resistant tuberculosis: highlighting a research gap.
Stagg, H
; Hatherell, H; Lipman, M; Harris, R; Abubakar, I and
(2016)
Treatment regimens for rifampicin-resistant tuberculosis: highlighting a research gap.
International Journal of Tuberculosis and Lung Disease, 20 (7).
pp. 866-869.
ISSN 1027-3719
DOI: 10.5588/ijtld.16.0034
; Hatherell, H; Lipman, M; Harris, R; Abubakar, I and
(2016)
Treatment regimens for rifampicin-resistant tuberculosis: highlighting a research gap.
International Journal of Tuberculosis and Lung Disease, 20 (7).
pp. 866-869.
ISSN 1027-3719
DOI: 10.5588/ijtld.16.0034
Treatment guidance for non-multidrug-resistant (MDR) rifampicin-resistant (RMP-R) tuberculosis (TB) is variable. We aimed to undertake a systematic review and meta-analysis of the randomised controlled trial (RCT) data behind such guidelines to identify the most efficacious treatment regimens. Ovid MEDLINE, the Web of Science and EMBASE were mined using search terms for TB, drug therapy and RCTs. Despite 12 604 records being retrieved, only three studies reported treatment outcomes by regimen for patients with non-MDR RMP-R disease, preventing meta-analysis. Our systematic review highlights a substantial gap in the literature regarding evidence-based treatment regimens for RMP-R TB.
-
picture_as_pdf - Stagg_etal_2016_Treatment-regimens-for-rifampicin-resistant.pdf
-
subject - Accepted Version
-
error - This is an author accepted manuscript version of an article accepted for publication, and following peer review. Please be aware that minor differences may exist between this version and the final version if you wish to cite from it.
-
- Available under Creative Commons: Attribution-NonCommercial-No Derivative Works 4.0
Downloads